Related Experiment Video
Updated: May 20, 2026
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
[Janus kinase inhibitors]
E Ostermeier1, P Roll, H-P Tony
1Med. Klinik und Poliklinik II, Sektion Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Deutschland. Ostermeier_E@klinik.uni-wuerzburg.de
Zeitschrift Fur Rheumatologie
|July 18, 2012
Summary
Janus kinase (JAK) inhibitors like tofacitinib show over 50% efficacy for rheumatoid arthritis treatment. Safety profiles are comparable to biologics, with common side effects including upper respiratory and urogenital infections.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Context:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease.
- Janus kinase (JAK) inhibitors represent a novel therapeutic class for RA.
- Tofacitinib is an oral JAK inhibitor.
Purpose:
- To evaluate the clinical efficacy and safety of tofacitinib in rheumatoid arthritis patients.
- To assess American College of Rheumatology (ACR) 20 response rates.
- To compare the safety profile of tofacitinib with existing biological therapies.
Summary:
- Tofacitinib demonstrated significant clinical efficacy in Phase II and III studies, achieving ACR20 response rates exceeding 50% in both monotherapy and combination with methotrexate (MTX).
- The safety profile of tofacitinib is comparable to established biological treatments for RA.
- The incidence of serious infections was low (3/100 patient-years), with common adverse events including upper respiratory tract and urogenital infections.
Impact:
- Tofacitinib offers a new oral treatment option for rheumatoid arthritis patients.
- The findings support JAK inhibitors as a viable therapeutic strategy for RA management.
- Understanding the safety profile, including common adverse events, is crucial for clinical practice.
More Related Videos
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...